Cancer jab shows promise in early trial results

A vaccine designed to prime the body to recognise and fight cancer cells has shown it could stimulate the immune system to help treat the disease more effectively, according to the results of an early trial.

Researchers described the results as “an important first step” in potentially developing a new treatment for people with advanced cancers.

The jab, known as mRNA-4359 and developed by Moderna, is aimed at people with advanced melanoma, lung cancer and other solid tumour cancers.

It uses mRNA technology, similar to Covid-19 vaccines, which teaches the immune system how cancer cells differ to healthy cells and mobilises it to destroy them.

For the first in-human study of the treatment, 19 patients with advanced solid tumours were given between one and nine doses of mRNA-4359.

Researchers found tumours did not grow and no new tumours appeared in eight of the 16 patients who were evaluated.

They also said the treatment was “well tolerated without serious side effects”.

“Important first step”

The results will be presented at the European Society of Medical Oncology conference in Barcelona by UK chief investigator Dr Debashis Sarker, a clinical reader in experimental oncology at King’s College London and a consultant in medical oncology at Guy’s & St Thomas’ NHS Foundation trust.

He said: “This study evaluating an mRNA cancer immunotherapy is an important first step in hopefully developing a new treatment for patients with advanced cancers.

“We have shown that the therapy is well tolerated without serious side effects and can stimulate the body’s immune system in a way that could help to treat cancer more effectively.

“However, as this study has only involved a small number of patients to date, it’s too early to say how effective this could be for people with advanced stage cancer.”

An 81-year-old man was the first person in the UK to receive the mRNA-4359 jab at Hammersmith Hospital in late October.

The patient – who wished to remain anonymous – has malignant melanoma skin cancer which is not responding to treatment.

The study is currently enrolling patients with specific cancers – namely melanoma and non-small-cell lung cancer – to have low doses of mRNA-4359 with pembrolizuma, also known as Keytruda.

Dr Sarkar described this as “a huge international effort across the UK, USA, Spain and Australia”.

Kyle Holen, senior vice president and health of development, therapeutics and oncology at Moderna, added: “We are encouraged by the phase 1 results of mRNA-4359, which demonstrate its potential to elicit strong antigen-specific T-cell responses while maintaining a manageable safety profile.

“This novel approach could be a key component in shifting the tumour microenvironment toward a more immune-permissive state, offering potential hope for patients with advanced solid tumours.”

The mRNA-4359 trial is one of a number of studies testing the effectiveness of jabs that are designed to fight cancer.

This includes the phase 3 trial of a personalised mRNA jab for melanoma – mRNA-4157 (V940) – which was given to a British patient earlier this year.

Scientists use a tumour sample, along with DNA sequencing and artificial intelligence, to create a jab specific to the patient’s tumour.

Elsewhere, a lung cancer patient became the first in the UK to have a new vaccine to help fight the disease in August.

The trial of a jab called BNT116, made by BioNTech, is taking place across 34 research sites in seven countries, with six located in England and Wales.

It is hoped about 130 lung cancer patients will eventually be enrolled.

In July 2023, the Government signed an agreement with BioNTech to provide up to 10,000 patients with precision cancer immunotherapies by 2030.